XML 9 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 132,033 $ 150,279
Marketable securities available-for-sale 591,505 592,023
Accounts receivaAccounts receivables, net of allowance for doubtful accounts of $12,313 and $0 at March 31, 2024 and December 31, 2023, respectively. 44,161 40,607
Other receivables 1,993 3,926
Inventories, net 61,806 53,290
Prepaid expenses and other current assets 19,788 18,995
Total current assets 851,286 859,120
Property and equipment, net 36,413 37,297
Operating lease right-of-use assets 23,392 24,287
Goodwill 2,022 2,067
Other assets 73,452 74,325
Total assets 986,565 997,096
Current liabilities:    
Accounts payable 2,431 5,245
Accrued research and development 3,137 2,982
Accrued liabilities 45,841 49,448
Other current liabilities 4,593 4,520
current liabilities 56,002 62,195
Convertible Notes, net of debt discount of $2,516 and $2,802 at March 31, 2024 and December 31, 2023, respectively (Note 7) 222,984 222,698
Long-term portion of lease liabilities 28,559 29,720
CEPI accrual long-term 60,337 60,337
Other long-term liabilities 203 74
Total liabilities 368,085 375,024
Commitments and contingencies (Note 5)
Stockholders’ equity:    
Common stock: $0.001 par value; 278,000 shares authorized at March 31, 2023 and December 31, 2022; 128,472 shares and 127,604 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively 131 130
Preferred stock: $0.001 par value; 5,000 shares authorized at March 31, 2023 and December 31, 2022; zero shares outstanding at March 31, 2023 and December 31, 2022, respectively 0 0
Additional paid-in capital 1,562,027 1,554,634
Accumulated other comprehensive (loss) gain (4,373) (2,108)
Accumulated deficit (939,305) (930,584)
Total stockholders’ equity 618,480 622,072
Total liabilities and stockholders’ equity $ 986,565 $ 997,096